TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Study of Clofarabine in Patients With Relapsed or Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Multiple myeloma diagnosed by standard criteria.~2. Measurable levels of monoclonal protein in serum (\>= 0.5 g/dL) or urine (\>= 0.2 g/24 hr).~3. At least 1 prior therapies for multiple myeloma with documented evidence of progression on the most recent treatment.~4. Age 18 years or older.~5. ECOG performance status \<= 2.~6. Acceptable organ and marrow function as defined below:~   * Hemoglobin \>= 8 gm/dL~  * Absolute neutrophil count \>= 1,000/mm3~  * Platelets \>= 50,000/mm3~  * Total bilirubin \<= 2.5 X institutional upper limit of normal~  * AST, ALT \<= 2.5 X institutional upper limit of normal~  * Creatinine 1.5 x institutional upper limit of normal~  * Normal cardiac function as determined by standard institutional methods~7. Women of child bearing potential must agree to use adequate contraception prior to study entry and for the duration of study.~8. Ability to understand and the willingness to sign a written informed consent document.~Exclusion Criteria:~1. Receiving any other investigational agents.~2. Receiving concurrent steroids with a dose equivalent of prednisone of \>= 150 mg/month.~3. Pregnant or nursing.~4. Active systemic infection considered opportunistic, life threatening or clinically significant at the time of treatment.~5. Severe concurrent disease, including severe insulin-dependent diabetes, uncontrolled hypertension, transient ischemic attacks, uncontrolled symptomatic coronary artery disease, or symptomatic CNS involvement or psychiatric illness/social situations that would limit compliance with study requirements.~6. History of other malignancy except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast unless the subject has been off treatment and free from disease for \>= 3 years.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Clofarabine (Type: EXPERIMENTAL): 4 mg/m2 IV over 1 hour on days 1-5 of each 28 day cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: RECELL to Promote Healing Following Carbon Dioxide (CO2) Laser Treatment in Cosmetic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults 18 years or older~* Patients undergoing facelift with perioral CO2 laser treatment~* Skin that is Fitzpatrick Score 1 or 2~Exclusion Criteria:~* Prior perioral CO2 laser resurfacing~* Allergy to components of preparation system

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Right receives ReCell (A) (Type: OTHER): Right perioral area of face receives ReCell/ Left receives saline
- Left receives ReCell (B) (Type: OTHER): Left perioral area of face receives ReCell/ Right receives saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Antineoplaston Therapy in Treating Patients With Stomach Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically proven adenocarcinoma of the stomach that is unlikely to respond to existing therapy, including surgery, radiotherapy, and chemotherapy~  * Evidence of tumor by MRI, CT scan, chest x-ray, or radionuclide scan~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* Karnofsky 60-100%~Life expectancy:~* At least 2 months~Hematopoietic:~* WBC at least 2,000/mm\^3~* Platelet count at least 50,000/mm\^3~Hepatic:~* No hepatic insufficiency~* Bilirubin no greater than 2.5 mg/dL~* SGOT and SGPT no greater than 5 times upper limit of normal~Renal:~* No renal insufficiency~* Creatinine no greater than 2.5 mg/dL~* No history of renal conditions that contraindicate high dosages of sodium~Cardiovascular:~* No known chronic heart failure~* No uncontrolled hypertension~* No history of congestive heart failure~* No history of other cardiovascular conditions that contraindicate high dosages of sodium~Pulmonary:~* No serious lung disease, such as chronic obstructive pulmonary disease~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception during and for 4 weeks after study participation~* Not a high medical or psychiatric risk~* No concurrent nonmalignant systemic disease~* No active infection~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* At least 4 weeks since prior immunotherapy~* No concurrent immunomodulating agents~Chemotherapy:~* At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered~Endocrine therapy:~* Concurrent corticosteroids allowed~Radiotherapy:~* At least 8 weeks since prior radiotherapy and recovered~Surgery:~* Recovered from prior surgery~Other:~* Prior cytodifferentiating agents allowed~* No other concurrent antineoplastic agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Antineoplaston therapy (Type: EXPERIMENTAL): Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Description of the Evolution of Functional Dysphonia Managed by Hypnotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of functional neurological disorder according to the DSM-5~* Supported at the Rothschild Foundation as part of a hypnotherapy protocol~* Mastering the understanding of the French language~* Express consent to participate in the study~Exclusion Criteria:~* Organic etiology of dysphonia~* Decompensation of a psychiatric pathology~* Discovery during study of an organic etiology not initially identified

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 95 Years
- Healthy Volunteers: None

Study Arms:
- Cohort (Type: None): Patients with functional dysphonia using the Voice Handicap Index score.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Intravenous GC4419 on the Incidence and Severity of Esophagitis Due to Chemoradiotherapy for Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects scheduled to be treated with (definitive or adjuvant) radiation therapy in combination with chemotherapy once daily for Stage 3A/3B or post-operative Stage 2B NSCLC or limited stage SCLC~2. Treatment plan for subjects show that 5 cm of the esophagus for at least one surface, is included in the 60 Gy isodose volume. Dose volume histograms show esophagus dose exposure meet V38\>30% and/or V60\>20%~3. Age 18 years or older~4. ECOG performance status ≤ 2~5. Adequate hematologic, renal and liver function~6. Use of highly effective contraception~Exclusion Criteria:~1. Metastatic disease~2. Prior radiation therapy to the region of the study cancer~3. Subjects not receiving chemotherapy~4. Grade 2 or greater esophagitis at baseline~5. Inability to provide information in the electronic symptom-reporting device~6. Receiving any approved or investigational immunotherapy, targeted therapy, hormone therapy, or biologic therapy~7. Participation in another clinical trial or use of another investigational agent within 30 days of first does of GC4419~8. Malignant tumors other than the current lung cancer within the last 5 years~9. Previous diagnosis of pneumonitis~10. Untreated, active infectious disease requiring systemic anti-infective therapy~11. Untreated HIV or active hepatitis B/C~12. Females who are pregnant or breastfeeding~13. Known allergies or intolerance to chemotherapy and similar platinum-containing compounds~14. Requirement for concurrent treatment with nitrates or other drugs that may create a risk for a precipitous decrease in blood pressure~15. Clinically significant heart disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GC4419 (avasopasem manganese) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study on Improvement of Blood Glucose Control in Patients With Diabetes Type 2 Using SMBG

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age:= and \>20 years. 2. Intend to paticipate in this study after education of structured testing. 3.HbA1c:= and \>7.5% in the recect 2 months.~Exclusion Criteria:~1.Pregancy. 2. Heavy complication 3. judged unsuitable by doctor

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- Single arm (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Zip-Stitch™ for Vaginal Cuff Closure in Laparoscopic Hysterectomy - Safety & Efficacy Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Provision of signed and dated Informed Consent Form 2. Stated willingness to comply with all study procedures, including participation in follow-up visits and telephonic follow-up 3. Female 18 years and older 5. Indicated for Laparoscopic Hysterectomy (may include TLH, LAVH, robotic assisted vaginal hysterectomy)~Exclusion Criteria:~1. History of HIV~2. History of Hepatitis C~3. History of diabetes, that in the opinion of the investigator may delay healing~4. Current use of systemic corticosteroids~5. Active infection of genitals, vagina, cervix, uterus or urinary tract~6. Active bacteremia, sepsis or other active systemic infection~7. Presence of Sexually Transmitted Infection (STI)~8. Evidence of pelvic inflammatory disease (PID)~9. Known clotting defects or bleeding disorders~10. Hemoglobin \< 8 g/dL~11. Metastatic disease~12. On anticoagulant therapy~13. Participation in another interventional trial~14. Pregnancy~15. Abnormal PAP results that have not been fully evaluated, or in the opinion of the investigator may indicate abnormal vaginal cuff healing~16. Co-morbidities that, in the opinion of the investigator, may indicate risk of abnormal vaginal cuff healing~17. Intra-op: Bowel injury during laparoscopic hysterectomy procedure prior to attempted cuff closure~16. Intra-op: Bladder injury during laparoscopic hysterectomy procedure prior to attempted cuff closure 17. Intra-op: Cases in which surgeon cannot identify adequate tissue along the cuff to apply suture laparoscopically 18. Intra-op: Cases requiring conversion to laparotomy prior to study intervention

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Test Article - Zip-stitch Clips (Type: EXPERIMENTAL): Zip-stitch clips for vaginal cuff closure during laparoscopic hysterectomy
- Reference Group - V-Loc Barbed Suture (Type: OTHER): Will not be comparative against the test article, but will be performed for reference and safety.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phosphodiesterase (PDE) Inhibitors Effect on Cognitive Deficits Associated to Schizophrenia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: TRIPLE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed Schizophrenia (WHO ICD 10)~* Treatment stable (no regulation in medicine for 6 weeks prior)~* Mono antipsychotic treatment~* No regular Antidepressants (PN accepted)~* No regular Benzodiazepines (PN accepted)~Exclusion Criteria:~* Dependence syndrome~* Severe physical illness~* MRI incompatible, non removable objects above shoulders

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Papaverine (Type: EXPERIMENTAL): Patients will receive either Papaverine or placebo added to their current medical treatment. Then after one week, they will receive the other treatment (if it was placebo first, then it will be papaverine; if it was papaverine first, then it will be placebo)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-318 in Subjects With MPS I

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ≥ 5 years of age~* Clinical diagnosis of attenuated MPS I deficiency (Hurler-Scheie, Scheie, or Hurlers status post-HSCT)~Exclusion Criteria:~* Known to be unresponsive to ERT~* Neutralizing antibodies to AAV 2/6~* Serious intercurrent illness or clinically significant organic disease (unless secondary to MPS I)~* Receiving antiviral therapy for hepatitis B or C, or with active hepatitis B or hepatitis C or HIV 1/2~* Lack of tolerance to laronidase treatment with significant IARs or occurrence of anaphylaxis~* Markers of hepatic dysfunction~* Creatinine ≥ 1.5 mg/dL~* Contraindication to the use of corticosteroids for immunosuppression~* Current treatment with systemic (IV or oral) immunomodulatory agent or steroid use (topical treatment allowed)~* Participation in prior investigational drug or medical device study within the previous 3 months~* Prior treatment with a gene therapy product~* Elevated or abnormal circulating α-fetoprotein (AFP)~* Weight \<20 kg at Screening Visit

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1: SB-318: Starting Dose 1.00E+13 vg/kg (Type: EXPERIMENTAL): A single dose of each of the three components of SB-318 \[zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)\] administered via intravenous (IV) infusion.
- Cohort 2: SB-318 at Next Ascending Dose 5.00E+13 vg/kg (Type: EXPERIMENTAL): A single dose of each of the three components of SB-318 \[zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)\] administered via intravenous (IV) infusion.
- Cohort 3: SB-318 at Next Ascending Dose 1.20E+14 vg/kg (Type: EXPERIMENTAL): A single dose of each of the three components of SB-318 \[zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)\] administered via intravenous (IV) infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Study of Lovastatin as Breast Cancer Chemoprevention

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
INCLUSION CRITERIA~* Female~* Increased inherited risk of breast cancer, as defined by:~  * Known deleterious mutation in BRCA1, BRCA2, or other high-risk mutation~ * Family history conveying at least a 2-fold increase in breast cancer risk~* ECOG performance status 0~* Normal organ and marrow function, including complete blood count and comprehensive metabolic panel within normal institutional limits~* Subject agreement to limit alcoholic beverage consumption to three alcoholic drinks per week.~EXCLUSION CRITERIA~* Prior history of invasive breast cancer less than 2 years previously (EXCEPTION: stage III or lower breast cancer \> 2 years ago)~* Current or history of other cancers (EXCEPTION: non-melanoma skin cancer, or stage III or cancer without evidence of recurrence for 5 years~* Initial mammogram, breast MRI, or clinical breast examination prompts recommendation for biopsy by study investigators.~* Evidence of malignant cytology on initial rpFNA.~* Use of other investigational agents.~* Use of tamoxifen or selective estrogen response modifiers (SERMS), including raloxifene, within the last 2 years.~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to lovastatin.~* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection; symptomatic congestive heart failure; unstable angina pectoris; cardiac arrhythmia; or psychiatric illness/social situations that would limit compliance with study requirements.~* Currently receiving lovastatin and cyclosporine, gemfibrozil, erythromycin, fibrates or niacin, (unless discontinued for study participation)~* No evidence of active liver disease, nor elevation of serum transaminases (prior history of liver disease, if not currently active, is not an exclusion)~* No evidence of myopathy or myositis, including symptoms of generalized muscle aches or weakness, muscle tenderness, or elevation in creatine phosphokinase.~* Lactating (breastfeeding)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Lovastatin 80 mg/day (Type: EXPERIMENTAL): Lovastatin 80 mg/day as 40 mg orally twice daily, for 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Memantine and Antipsychotics Use

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Current diagnosis of probable Alzheimer's disease consistent with NINCDS-ADRDA criteria or with DSM IV TR criteria for Dementia of the Alzheimer's type.~* MRI or CT scan supporting the diagnosis of DAT without indications of any relevant other CNS disorders.~* Patients treated with any acetylcholinesterase inhibitor (AChEI) man be included.~* The patient should have German as a mother-tongue or at least speak the language fluently.~Exclusion criteria:~* Evidence (including CT/MRI results) of any clinically significant central nervous system disease other than Alzheimer's disease.~* Modified Hachinski Ischemia score greater than 4 at screening.~* Intake of any medication that is contra-indicated in combination with memantine.~* Treatment with depot antipsychotics.~* History of severe drug allergy, or hypersensitivity, or patients with known hypersensitivity to memantine, amantadine or lactose.~* Known or suspected history of alcoholism or drug abuse within the past 10 years.~* Previous treatment with memantine or participation in an investigational study with memantine.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Memantine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cervical Pessary to Prevent Preterm Birth in Singleton Pregnancies With a Sonographically Measured Short Cervix

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* singleton~* cervical length \< 25 mm measured by transvaginal ultrasound prior to 23 weeks 0 days~* agrees to refrain from sexual intercourse~Exclusion Criteria:~* major fetal anomalies~* painful regular uterine contractions~* active vaginal bleeding~* ruptured membranes~* evidence of chorioamnionitis or other maternal/fetal infectious morbidity~* placenta previa~* cervical cerclage in situ~* visual cervical dilation of 2 cm or greater with visible amnion/chorion~* significant maternal-fetal complications (chronic hypertension, insulin dependent diabetes mellitus, systemic lupus erythematosus with nephritis, chronic hypertension, red cell alloimmunization, drug abuse)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Device: Arabin Pessary (Type: EXPERIMENTAL): Participants randomized to this group will receive the pessary.
- Standard of Care (Type: NO_INTERVENTION): Patients randomized to the control group will receive standard of care for their condition. This includes surveillance of cervical length, vaginal progesterone, and emergency cerclage.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues